{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T18:45:12Z","timestamp":1769280312957,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Cancer Center of China","award":["NCC201909B03"],"award-info":[{"award-number":["NCC201909B03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-04562-8","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:42:48Z","timestamp":1751420568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The value of MRI-based radiomics and clinicoradiological data for the detection of forkhead box protein A1 gene mutated prostate cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Lin","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingni","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hualei","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kefu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"4562_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren, O. et al. 2022 update on prostate cancer epidemiology and risk factors: A systematic review. Eur. Urol. 84, 191\u2013206 (2023).","journal-title":"Eur. Urol."},{"key":"4562_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/ncponc0765","volume":"4","author":"ME Taplin","year":"2007","unstructured":"Taplin, M. E. Drug insight: Role of the androgen receptor in the development and progression of prostate cancer. Nat. Clin. Pract. Oncol. 4, 236\u2013244 (2007).","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"4562_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","volume":"22","author":"JE Vellky","year":"2020","unstructured":"Vellky, J. E. & Ricke, W. A. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia 22, 566\u2013575 (2020).","journal-title":"Neoplasia"},{"key":"4562_CR4","doi-asserted-by":"publisher","first-page":"e695","DOI":"10.1002\/ctm2.695","volume":"12","author":"CF Lee","year":"2022","unstructured":"Lee, C. F. et al. The central role of sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC. Clin. Transl. Med. 12, e695 (2022).","journal-title":"Clin. Transl. Med."},{"key":"4562_CR5","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1002\/1878-0261.13497","volume":"17","author":"SI Celada","year":"2023","unstructured":"Celada, S. I. et al. Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer. Mol. Oncol. 17, 2126\u20132146 (2023).","journal-title":"Mol. Oncol."},{"key":"4562_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso, C. S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239\u2013243 (2012).","journal-title":"Nature"},{"key":"4562_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","volume":"571","author":"EJ Adams","year":"2019","unstructured":"Adams, E. J. et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature 571, 408\u2013412 (2019).","journal-title":"Nature"},{"key":"4562_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1365-2559.2011.03796.x","volume":"58","author":"RK Jain","year":"2011","unstructured":"Jain, R. K., Mehta, R. J., Nakshatri, H., Idrees, M. T. & Badve, S. S. High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology 58, 766\u2013772 (2011).","journal-title":"Histopathology"},{"key":"4562_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12672-023-00777-1","volume":"14","author":"D Feng","year":"2023","unstructured":"Feng, D. et al. Senescence-associated secretory phenotype constructed detrimental and beneficial subtypes and prognostic index for prostate cancer patients undergoing radical prostatectomy. Discov. Oncol. 14, 155 (2023).","journal-title":"Discov. Oncol."},{"key":"4562_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/pros.24817","volume":"85","author":"H Tao","year":"2025","unstructured":"Tao, H. et al. Efficacy and predictive factors analysis of androgen deprivation plus novel hormone therapy as neoadjuvant treatment for high-risk prostate cancer. Prostate 85, 198\u2013206 (2025).","journal-title":"Prostate"},{"key":"4562_CR11","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/1878-0261.13511","volume":"17","author":"Y Wei","year":"2023","unstructured":"Wei, Y. et al. Prospective clinical sequencing of 1016 Chinese prostate cancer patients: Uncovering genomic characterization and race disparity. Mol. Oncol. 17, 2183\u20132199 (2023).","journal-title":"Mol. Oncol."},{"key":"4562_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","volume":"601","author":"L Xiao","year":"2022","unstructured":"Xiao, L. et al. Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer. Nature 601, 434\u2013439 (2022).","journal-title":"Nature"},{"key":"4562_CR13","doi-asserted-by":"crossref","unstructured":"Hwang, K. W., Yun, J. W. & Kim, H. S. Unveiling the molecular landscape of FOXA1 mutant prostate cancer: Insights and prospects for targeted therapeutic strategies. Int. J. Mol. Sci. 24 (2023).","DOI":"10.3390\/ijms242115823"},{"key":"4562_CR14","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Prostate cancer (version 2.2019) (2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"4562_CR15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JCO.2017.74.1173","volume":"36","author":"VN Giri","year":"2018","unstructured":"Giri, V. N. et al. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017. J. Clin. Oncol. 36, 414\u2013424 (2018).","journal-title":"J. Clin. Oncol."},{"key":"4562_CR16","doi-asserted-by":"crossref","unstructured":"Wyatt, A. W. et al. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J. Natl. Cancer Inst. 109 (2017).","DOI":"10.1093\/jnci\/djx118"},{"key":"4562_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","volume":"29","author":"KN Chi","year":"2023","unstructured":"Chi, K. N. et al. Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound. Clin. Cancer Res. 29, 81\u201391 (2023).","journal-title":"Clin. Cancer Res."},{"key":"4562_CR18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2018.08.009","volume":"75","author":"M L\u00f8vf","year":"2019","unstructured":"L\u00f8vf, M. et al. Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. Eur. Urol. 75, 498\u2013505 (2019).","journal-title":"Eur. Urol."},{"key":"4562_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.humpath.2010.02.011","volume":"41","author":"M Andreoiu","year":"2010","unstructured":"Andreoiu, M. & Cheng, L. Multifocal prostate cancer: Biologic, prognostic, and therapeutic implications. Hum. Pathol. 41, 781\u2013793 (2010).","journal-title":"Hum. Pathol."},{"key":"4562_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","volume":"18","author":"MC Haffner","year":"2021","unstructured":"Haffner, M. C. et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat. Rev. Urol. 18, 79\u201392 (2021).","journal-title":"Nat. Rev. Urol."},{"key":"4562_CR21","doi-asserted-by":"publisher","first-page":"14951","DOI":"10.1038\/s41598-024-65354-0","volume":"14","author":"H Sherafatmandjoo","year":"2024","unstructured":"Sherafatmandjoo, H., Safaei, A. A., Ghaderi, F. & Allameh, F. Prostate cancer diagnosis based on multi-parametric MRI, clinical and pathological factors using deep learning. Sci. Rep. 14, 14951 (2024).","journal-title":"Sci. Rep."},{"key":"4562_CR22","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1007\/s00330-021-08520-6","volume":"32","author":"Y Qi","year":"2022","unstructured":"Qi, Y., Zhao, T. & Han, M. The application of radiomics in predicting gene mutations in cancer. Eur. Radiol. 32, 4014\u20134024 (2022).","journal-title":"Eur. Radiol."},{"key":"4562_CR23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/MOU.0000000000000902","volume":"31","author":"R Thenault","year":"2021","unstructured":"Thenault, R., Gasmi, A., Khene, Z. E., Bensalah, K. & Mathieu, R. Radiogenomics in prostate cancer evaluation. Curr. Opin. Urol. 31, 424\u2013429 (2021).","journal-title":"Curr. Opin. Urol."},{"key":"4562_CR24","doi-asserted-by":"publisher","first-page":"109875","DOI":"10.1016\/j.radonc.2023.109875","volume":"188","author":"VE Skingen","year":"2023","unstructured":"Skingen, V. E. et al. Prostate cancer radiogenomics reveals proliferative gene expression programs associated with distinct MRI-based hypoxia levels. Radiother. Oncol. 188, 109875 (2023).","journal-title":"Radiother. Oncol."},{"key":"4562_CR25","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/jmri.29186","volume":"60","author":"R Chen","year":"2024","unstructured":"Chen, R. et al. Association of pathological features and multiparametric MRI-based radiomics with TP53-mutated prostate cancer. J. Magn. Reson. Imaging 60, 1134\u20131145 (2024).","journal-title":"J. Magn. Reson. Imaging"},{"key":"4562_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/pcan.2010.16","volume":"14","author":"M Karavitakis","year":"2011","unstructured":"Karavitakis, M. et al. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: Implications for focal therapy. Prostate Cancer Prostatic Dis. 14, 46\u201352 (2011).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"4562_CR27","doi-asserted-by":"publisher","first-page":"110763","DOI":"10.1016\/j.ejrad.2023.110763","volume":"162","author":"S Ghafoor","year":"2023","unstructured":"Ghafoor, S. et al. Index lesion contouring on prostate MRI for targeted MRI\/US fusion biopsy: Evaluation of mismatch between radiologists and urologists. Eur. J. Radiol. 162, 110763 (2023).","journal-title":"Eur. J. Radiol."},{"key":"4562_CR28","doi-asserted-by":"publisher","first-page":"e223349","DOI":"10.1148\/radiol.223349","volume":"309","author":"S Luzzago","year":"2023","unstructured":"Luzzago, S. et al. Multiparametric MRI-based 5-year risk prediction model for biochemical recurrence of prostate cancer after radical prostatectomy. Radiology 309, e223349 (2023).","journal-title":"Radiology"},{"key":"4562_CR29","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","volume":"31","author":"PA Yushkevich","year":"2006","unstructured":"Yushkevich, P. A. et al. User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability. Neuroimage 31, 1116\u20131128 (2006).","journal-title":"Neuroimage"},{"key":"4562_CR30","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","volume":"77","author":"J van Griethuysen","year":"2017","unstructured":"van Griethuysen, J. et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 77, e104\u2013e107 (2017).","journal-title":"Cancer Res."},{"key":"4562_CR31","doi-asserted-by":"crossref","unstructured":"Chawla, N. V., Bowyer, K. W., Hall, L. O. & Kegelmeyer, W. P. SMOTE: Synthetic minority over-sampling technique. J. Artif. Intell. Res. 321\u2013357 (2002)","DOI":"10.1613\/jair.953"},{"key":"4562_CR32","doi-asserted-by":"crossref","unstructured":"Dong, H. Y. et al. FOXA1 in prostate cancer. Asian J. Androl. (2022).","DOI":"10.4103\/aja202259"},{"key":"4562_CR33","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ajpath.2011.10.021","volume":"180","author":"J Gerhardt","year":"2012","unstructured":"Gerhardt, J. et al. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am. J. Pathol. 180, 848\u2013861 (2012).","journal-title":"Am. J. Pathol."},{"key":"4562_CR34","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1158\/1078-0432.CCR-19-1669","volume":"26","author":"FA Faisal","year":"2020","unstructured":"Faisal, F. A. et al. CDKN1B Deletions are associated with metastasis in African American men with clinically localized, surgically treated prostate cancer. Clin. Cancer Res. 26, 2595\u20132602 (2020).","journal-title":"Clin. Cancer Res."},{"key":"4562_CR35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","volume":"571","author":"A Parolia","year":"2019","unstructured":"Parolia, A. et al. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature 571, 413\u2013418 (2019).","journal-title":"Nature"},{"key":"4562_CR36","doi-asserted-by":"crossref","unstructured":"Jozwiak, R., Sobecki, P. & Lorenc, T. Intraobserver and interobserver agreement between six radiologists describing mpMRI features of prostate cancer using a PI-RADS 2.1 structured reporting scheme. Life (Basel) 13 (2023).","DOI":"10.3390\/life13020580"},{"key":"4562_CR37","doi-asserted-by":"publisher","first-page":"20190373","DOI":"10.1259\/bjr.20190373","volume":"92","author":"Y Sun","year":"2019","unstructured":"Sun, Y. et al. Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: A pilot study. Br. J. Radiol. 92, 20190373 (2019).","journal-title":"Br. J. Radiol."},{"key":"4562_CR38","doi-asserted-by":"crossref","unstructured":"Ogbonnaya, C. N. et al. Radiogenomics reveals correlation between quantitative texture radiomics features of biparametric MRI and hypoxia-related gene expression in men with localised prostate cancer. J. Clin Med. 12 (2023).","DOI":"10.3390\/jcm12072605"},{"key":"4562_CR39","doi-asserted-by":"publisher","first-page":"906370","DOI":"10.3389\/fonc.2022.906370","volume":"12","author":"Q Ge","year":"2022","unstructured":"Ge, Q. et al. Neoadjuvant chemohormonal therapy in prostate cancer before radical prostatectomy: A systematic review and meta-analysis. Front. Oncol. 12, 906370 (2022).","journal-title":"Front. Oncol."},{"key":"4562_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12967-022-03846-1","volume":"21","author":"M Bauckneht","year":"2023","unstructured":"Bauckneht, M. et al. Gene\u2019s expression underpinning the divergent predictive value of [18F]F-fluorodeoxyglucose and prostate-specific membrane antigen positron emission tomography in primary prostate cancer: A bioinformatic and experimental study. J. Transl. Med. 21, 3 (2023).","journal-title":"J. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04562-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04562-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04562-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:42:52Z","timestamp":1751420572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04562-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4562"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04562-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"15 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22929"}}